Arbutus Biopharma Corp (ABUS): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of ABUS were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Arbutus Biopharma
From the latest filingsOverall: about as much buying as selling. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABUS
177 funds and institutions reported ABUS shares worth $681M at the end of Q2 2026, about 73% of the company. The largest holder is Two Seas Capital LP with 9.8%.
Funds and institutions (13F) 73%Everyone else 27%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Two Seas Capital LP | 19.10M | 9.77% | $91.7M | +3% |
| Morgan Stanley | 17.70M | 9.05% | $85M | -32% |
| Whitefort Capital Management, LP | 15.79M | 8.08% | $75.8M | +6% |
| BlackRock, Inc. | 13.77M | 7.04% | $66.1M | +6% |
| State Street Corp | 7.87M | 4.03% | $37.8M | +24% |
| Rubric Capital Management LP | 7.53M | 3.85% | $36.2M | +14% |
| Vanguard Capital Management LLC | 7.01M | 3.59% | $33.7M | +5% |
| Barclays PLC | 4.21M | 2.15% | $20.2M | -3% |
| Geode Capital Management, LLC | 4.12M | 2.11% | $19.8M | +9% |
| Goldman Sachs Group Inc | 3.51M | 1.79% | $16.8M | +219% |
| Bank of America Corp | 2.65M | 1.35% | $12.7M | +57% |
| BlackBarn Capital Partners LP | 2.50M | 1.28% | $12M | No change |
| Legal & General Group Plc | 2.47M | 1.26% | $11.8M | +3% |
| Woodline Partners LP | 2.28M | 1.17% | $11M | +14% |
| Jefferies Financial Group Inc. | 1.71M | 0.88% | $8.2M | -10% |
| Nomura Holdings Inc | 1.64M | 0.84% | $7.9M | – |
| Vanguard Portfolio Management LLC | 1.54M | 0.79% | $7.4M | +11% |
| Charles Schwab Investment Management Inc | 1.43M | 0.73% | $6.9M | +2% |
| Sixth Street Partners Management Company, L.P. | 1.43M | 0.73% | $6.9M | – |
| Northern Trust Corp | 1.42M | 0.73% | $6.8M | +11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No ABUS insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABUS short interest
High short interest. 10.1% of ABUS shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 19.89M ABUS shares were sold short, 10.1% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 2.18M shares, buying them all back would take about 9.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 19.89M | 10.05% | -19% | 2.18M | 9.1 |
| Oct 15, 2026 | 24.57M | 12.42% | -28% | 5.66M | 4.3 |
| Sep 30, 2026 | 34.05M | 17.21% | +84% | 9.65M | 3.5 |
| Sep 15, 2026 | 18.48M | 9.34% | -2% | 3.69M | 5.0 |
| Aug 31, 2026 | 18.92M | 9.56% | +2% | 6.14M | 3.1 |
| Aug 14, 2026 | 18.46M | 9.33% | -9% | 1.22M | 15.1 |
| Jul 31, 2026 | 20.24M | 10.35% | +3% | 1.48M | 13.7 |
| Jul 15, 2026 | 19.65M | 10.05% | +15% | 2.66M | 7.4 |
| Jun 30, 2026 | 17.11M | 8.75% | -2% | 3.50M | 4.9 |
| Jun 15, 2026 | 17.52M | 8.96% | +3% | 1.26M | 14.0 |
| May 29, 2026 | 16.98M | 8.69% | +3% | 1.85M | 9.2 |
| May 15, 2026 | 16.44M | 8.41% | -7% | 962,486 | 17.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Arbutus Biopharma company events
Arbutus Biopharma filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 22, 2026AnnouncementArbutus Biopharma Corporation issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company’s oral PD-L1 inhibitor. Filing
- Aug 21, 2026AnnouncementArbutus Biopharma Corporation issued a press release announcing its plans to launch a modified “Dutch auction” tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 16, 2026LeadershipPursuant to the Settlement Agreement with Moderna described in Item 1.02 above, Moderna made an aggregate $950 million noncontingent lump sum payment to Arbutus and Genevant on July 8, 2026. Filing
- May 27, 2026LeadershipArbutus Biopharma Corporation held its 2026 Annual General and Special Meeting of Shareholders. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 15, 2026AnnouncementArbutus Biopharma Corporation issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of… Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Mar 3, 2026AgreementArbutus Biopharma Corporation, Genevant Sciences GmbH, and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending… Filing
- Feb 20, 2026AnnouncementThe U.S. District Court for the District of Delaware issued a memorandum and order in the litigation filed by Arbutus Biopharma Corporation and its licensee, Genevant Sciences GmbH (collectively with its affiliates, “Genevant”), against Moderna Inc. and a Moderna affiliate (collectively, “Moderna”)… Filing
- Feb 6, 2026AnnouncementThe U.S. District Court for the District of Delaware issued a memorandum and order in the litigation filed by Arbutus Biopharma Corporation and its licensee, Genevant Sciences GmbH (collectively with its affiliates, “Genevant”), against Moderna Inc. and a Moderna affiliate (collectively, “Moderna”)… Filing
- Jan 16, 2026AnnouncementThe Board of Appeal of the European Patent Office revoked Arbutus Biopharma Corporation’s European patent EP 2279254. Filing
- Dec 11, 2025AnnouncementLindsay Androski, Chairperson, Chief Executive Officer and President of Arbutus Biopharma Corporation will give a presentation regarding the Company’s ongoing lawsuits against Moderna Therapeutics, Inc., Pfizer Inc. and BioNTech SE, for their use of the Company’s patented lipid nanoparticle… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arbutus Biopharma financials
Famous investors that hold ABUS
2 of the 50 well-known investors we track reported holding ABUS in their latest 13F filing. The largest position is Israel Englander's, worth $14.6M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.06M | $14.6M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 82,314 | $393K | 0.0% | -80% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named ABUS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | NOMURA HOLDINGS INC | 13G | 7.3% |
| Nov 16, 2026 | NOMURA HOLDINGS INC | 13G | 7.3% |
| Nov 16, 2026 | Whitefort Capital Master Fund, LP | 13G/A | 1.6% |
| Nov 16, 2026 | Two Seas Capital LP | 13G/A | 4.1% |
| Nov 16, 2026 | Two Seas Capital LP | 13G/A | 4.1% |
| Nov 16, 2026 | Whitefort Capital Master Fund, LP | 13G/A | 1.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.2% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.2% |
| Oct 7, 2026 | Morgan Stanley | 13G/A | 12.2% |
| Oct 7, 2026 | Morgan Stanley | 13G/A | 12.2% |
| Oct 5, 2026 | Roivant Sciences Ltd. | 13D/A | 19.5% |
| Oct 5, 2026 | Roivant Sciences Ltd. | 13D/A | 19.5% |
Questions about Arbutus Biopharma Corp (ABUS) stock
Who owns the most ABUS stock?
The largest reported owner of Arbutus Biopharma Corp (ABUS) is Two Seas Capital LP, with 9.8% of the company. In total, 177 funds and institutions reported holding ABUS at the end of Q2 2026, together about 73% of the shares. See the largest owners.
Are ABUS insiders buying or selling?
No ABUS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in ABUS?
As of Oct 30, 2026, 19.89M ABUS shares were sold short, 10.1% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 2.18M shares, buying them all back would take about 9.1 trading days (days to cover). See the history.
Which famous investors hold ABUS?
2 of the 50 well-known investors we track reported ABUS in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $14.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.